Huntington's disease: from molecular pathogenesis to clinical treatment

  title={Huntington's disease: from molecular pathogenesis to clinical treatment},
  author={Christopher A. Ross and Sarah J. Tabrizi},
  journal={The Lancet Neurology},
  • C. Ross, S. Tabrizi
  • Published 31 January 2011
  • Biology, Psychology, Medicine
  • The Lancet Neurology

Figures from this paper

Huntington's disease: a clinical review
Antisense oligonucleotide therapy is one such approach with clinical trials currently under way that may bring us one step closer to treating and potentially preventing this devastating condition.
Clinical Features of Huntington's Disease.
The epidemiology, genetics and pathogenesis of HD as well as the clinical presentation and management of HD, which is currently focused on symptomatic treatment are discussed.
Huntington's disease: fighting on many fronts.
Two articles in this issue of Brain highlight the Huntington's disease research community's multi-faceted approach to developing new treatments for Huntington’s disease.
Pathogenic insights from Huntington's disease-like 2 and other Huntington's disease genocopies.
It is suggested that HDL2 is a complex disease in which transcripts and proteins expressed bidirectionally from the junctophilin-3 locus contribute to pathogenesis through both gain-and loss-of-function mechanisms.
Huntington’s Disease: Molecular Pathogenesis and New Therapeutic Perspectives
The preclinical and clinical development molecular therapies targeting HTT expression and the modulation of biological mechanisms thought to contribute to disease pathogenesis via novel therapeutic agents are reviewed.
Neuroimmunology of Huntington's Disease: Revisiting Evidence from Human Studies
The current review summarizes the available evidence about immune and/or inflammatory changes in HD, which is associated with increased inflammatory mediators in both the central nervous system and periphery.
Molecular Mechanisms Underlying Neuropathology in Mouse Models of Huntington’s Disease
This dissertation will detail work performed in characterizing the cellular and molecular determinants of HD pathogenesis in novel mouse models developed in the Yang lab, using conditional genetics to define cells in the cortex and striatum as essential to developing HD phenotypes, and assessed molecular signatures in these cells that are dependent on the mutant huntingtin protein.
Huntington’s Disease: The Past, Present, and Future Search for Disease Modifiers
Although silencing Htt expression appears promising as a disease modifying treatment, it should be attempted with caution in light of Htt’s essential roles in neural maintenance and development.
A Clinical Review on Huntington Disease
  • P. Malkani
  • Biology, Medicine
    Global Journal of Pharmacy & Pharmaceutical Sciences
  • 2018
The mechanism by which neuronal degeneration and cell death are being generated in HD may include excitotoxicity, energy deficit, oxidative stress, inflammatory process and protein aggregation.
Preclinical and Clinical Investigations of Mood Stabilizers for Huntington's Disease: What Have We Learned?
Preclinical and clinical investigations of the beneficial effects of lithium and VPA on HD pathophysiology are discussed, including behavioral and motor improvement, enhanced neuroprotection, and lifespan extension.


Selective neuronal degeneration in Huntington's disease.
Pathogenic mechanisms in Huntington's disease.
Huntington's disease: from pathology and genetics to potential therapies.
Not all of the effects of mutant huntingtin may be cell-autonomous, and it is possible that abnormalities in neighbouring neurons and glia may also have an impact on connected cells.
Huntington's disease: phenomenological diversity of a neuropsychiatric condition that challenges traditional concepts in neurology and psychiatry.
The following case report emphasizes the spectrum and clinical significance of neuropsychiatric phenomena associated with Huntington’s disease and discusses the diagnostic power of specific neuropsychological approaches.
Global changes to the ubiquitin system in Huntington's disease
A mass-spectrometry-based method is exploited to quantify polyubiquitin chains and it is demonstrated that the abundance of these chains is a faithful endogenous biomarker of UPS function, establishing that UPS dysfunction is a consistent feature of HD pathology.